Iype P T, McMahon J B
Mol Cell Biochem. 1984;59(1-2):57-80. doi: 10.1007/BF00231305.
Although a long held tenet of biology has been that endogenous inhibitors can modulate cell proliferation, little progress was made in purifying any such inhibitor. This was largely due to the rarity of non-malignant cell cultures in which regulation of cell division was still operative, and to problems in separating cytotoxic and cytostatic effects in the complex biological extracts which were being studied. During the last decade, hepatic proliferation inhibitors of varying degrees of purity have been isolated using regenerating rat liver or hepatoma cell cultures as test systems. In these early studies, a number of inhibitors with differing molecular weights, physicochemical properties and biological responses were purified from liver cytosol and/or serum. Some of them could inhibit DNA synthesis or mitosis and thus were considered to be G1 or G2 inhibitors. However, experiments which could give precise answers about mechanisms of action could not be done until an inhibitor purified to homogeneity was available. Using well-characterized rat liver diploid epithelial cell cultures, which maintain a number of liver properties and which do not possess any transformation markers or malignant properties, we recently purified an hepatic proliferation inhibitor to a homogenous protein. It has a molecular weight of 26 000 daltons and an isoelectric point of 4.65. It specifically inhibits cell division and DNA synthesis in a number of non-malignant rat liver epithelial cell types, and has no effect on transformed liver cells, or hepatoma cells, in culture. Its effect is not mediated through destruction or sequestration of essential nutrients or calcium ions. Nor have preliminary experiments shown the hepatic proliferation inhibitor to interfere with the binding of epidermal growth factor to its receptors. The majority of the cells treated with the inhibitor are blocked in the G1 phase. Further experiments to study its mechanism of action and the inter-relationship, if any, between the cell cycle block induced by serum or nutrient deprivation, and the inhibitor-induced cycle block are in progress.
尽管生物学中一个长期存在的原则是内源性抑制剂可以调节细胞增殖,但在纯化任何此类抑制剂方面进展甚微。这主要是由于非恶性细胞培养物稀少,其中细胞分裂的调节仍然有效,以及在研究的复杂生物提取物中分离细胞毒性和细胞抑制作用存在问题。在过去十年中,使用再生大鼠肝脏或肝癌细胞培养物作为测试系统,分离出了不同纯度的肝脏增殖抑制剂。在这些早期研究中,从肝细胞溶胶和/或血清中纯化出了一些分子量、理化性质和生物学反应不同的抑制剂。其中一些可以抑制DNA合成或有丝分裂,因此被认为是G1或G2抑制剂。然而,直到获得纯化至同质的抑制剂,才能进行能够给出关于作用机制的确切答案的实验。使用特征明确的大鼠肝脏二倍体上皮细胞培养物,其保留了许多肝脏特性,且不具有任何转化标记或恶性特性,我们最近将一种肝脏增殖抑制剂纯化至同质蛋白。它的分子量为26000道尔顿,等电点为4.65。它特异性抑制多种非恶性大鼠肝脏上皮细胞类型的细胞分裂和DNA合成,对培养中的转化肝细胞或肝癌细胞没有影响。其作用不是通过破坏或隔离必需营养素或钙离子来介导的。初步实验也未表明肝脏增殖抑制剂会干扰表皮生长因子与其受体的结合。用该抑制剂处理的大多数细胞被阻断在G1期。正在进行进一步的实验,以研究其作用机制以及血清或营养剥夺诱导的细胞周期阻滞与抑制剂诱导的周期阻滞之间的相互关系(如果有的话)。